Mus vs Togo: HIV-positive TB patients on ART (antiretroviral therapy)
Mus
100.0%
in 2024
Togo
100.0%
in 2024
Mus rank
1st
Togo rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Mus
- Togo
How they compare
Mus currently reports 100.0% against 100.0% in Togo, a difference of 0.0%.
The two have swapped places 7 times across 17 shared years of data; in 2008 it was Mus ahead.
Mus ranks 1st and Togo ranks 1st of 2 regions.
Mus has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Mus | Togo | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 60.5% | 33.0% | 27.5% | Mus |
| 2010s | 86.2% | 85.1% | 1.1% | Mus |
| 2020s | 100.0% | 99.2% | 0.8% | Mus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Mus or Togo?
- Mus, at 100.0% against 100.0% in Togo as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Mus and Togo?
- 0.0%, with Mus ahead.
- How many years of comparable data are there for Mus and Togo?
- 17 years are reported by both, from 2008 to 2024.
- How do Mus and Togo rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Mus ranks 1st and Togo ranks 1st of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.